Frontiers in endocrinology · 2026
Effect of acupuncture pretreatment on clinical pregnancy rate in women with diminished ovarian reserve undergoing IVF-ET: study protocol for a multicenter randomized controlled trial.
СтатьяПротокол клинического исследованияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Xin, Su Chenchen, Li Junmin, Chen Li, Zhang Qinhua, Sun Yan, Xu Jinbang, Zhang Cuilian, Cheng Xinjie, Li Xuemei, Yang Huisheng, Xie Yicong, Yang Jie, Zhu Na, Lu Weiying, Su Tongsheng, Shang Wei, Lu Qun, Yang Li, Li Jiashan, Hang Tian, Qi Lingyu, Xiao Qiwei, Li Weixin, Gao Feng, Wang Xiaoyan, Du Pengfei, An Dongxue, Xu Huanfang, Fang Yigong
Аннотация
INTRODUCTION: Diminished ovarian reserve (DOR) is known to reduce the likelihood of achieving pregnancy or live births in women undergoing in vitro fertilization and embryo transfer (IVF-ET). Acupuncture maybe effective for DOR, but current evidence remains limited and inconclusive.
METHODS AND ANALYSIS: This study is a multicenter, randomized, placebo-controlled trial conducted on a large scale. A total of 300 women with DOR preparing for IVF-ET will be randomized 1:1 to acupuncture or placebo acupuncture. Interventions will be administered from the second menstrual cycle preceding the IVF cycle until the day of oocyte retrieval. The primary outcome is the clinical pregnancy rate (CPR) following the first embryo transfer. Secondary outcomes include various IVF-ET indicators, such as the number of follicles ≥ 14 mm, estradiol (E2) levels, and endometrial thickness on the day of human chorionic gonadotropin (hCG) administration; the number of retrieved oocytes, metaphase II (MII) oocytes, and two pronuclei (2PN) fertilizations; as well as the rates of 2PN fertilization, available embryos, high-quality embryos, implantation, cycle cancellation, biochemical pregnancy, pregnancy loss, sustained pregnancy, and live birth. Additionally, ovarian reserve indicators-including antral follicle count (AFC), basal serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and E2, and anti-Müllerian hormone (AMH)-along with scores from the Self-Rating Anxiety Scale (SAS) will also be evaluated.
ETHICS AND DISSEMINATION: The trial has been approved by the ethics committees of all participating centers. The results will be disseminated in academic journals.
CLINICAL TRIAL REGISTRATION: http://itmctr.ccebtcm.org.cn/, identifier ID: ITMCTR2024000021.
METHODS AND ANALYSIS: This study is a multicenter, randomized, placebo-controlled trial conducted on a large scale. A total of 300 women with DOR preparing for IVF-ET will be randomized 1:1 to acupuncture or placebo acupuncture. Interventions will be administered from the second menstrual cycle preceding the IVF cycle until the day of oocyte retrieval. The primary outcome is the clinical pregnancy rate (CPR) following the first embryo transfer. Secondary outcomes include various IVF-ET indicators, such as the number of follicles ≥ 14 mm, estradiol (E2) levels, and endometrial thickness on the day of human chorionic gonadotropin (hCG) administration; the number of retrieved oocytes, metaphase II (MII) oocytes, and two pronuclei (2PN) fertilizations; as well as the rates of 2PN fertilization, available embryos, high-quality embryos, implantation, cycle cancellation, biochemical pregnancy, pregnancy loss, sustained pregnancy, and live birth. Additionally, ovarian reserve indicators-including antral follicle count (AFC), basal serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and E2, and anti-Müllerian hormone (AMH)-along with scores from the Self-Rating Anxiety Scale (SAS) will also be evaluated.
ETHICS AND DISSEMINATION: The trial has been approved by the ethics committees of all participating centers. The results will be disseminated in academic journals.
CLINICAL TRIAL REGISTRATION: http://itmctr.ccebtcm.org.cn/, identifier ID: ITMCTR2024000021.